Biota Holdings Limited

Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that its second generation, influenza treatment, CS-8958, has successfully completed its initial Phase II clinical evaluation, showing favourable outcomes against all measured endpoints. The initial Phase III trial is scheduled to commence later this year. CS-8958 is a long acting neuraminidase inhibitor (LANI), and is co-owned with Daiichi-Sankyo Company Limited (TYO:4568).

Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that it had received written notification from GlaxoSmithKline (GSK) that indicative royalties from Relenza were $0.4m during the three months ended 30 June 2008, on sales of $6.2m.

Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced it had concluded its litigation against GlaxoSmithKline (GSK). The announcement followed formal mediation between by the parties ordered by the Victorian Supreme Court. The mediation provided the parties with the opportunity to resolve their differences and eliminate the uncertainty and costs associated with the legal process.

Biota Holdings Limited (ASX: BTA) today announced that its long acting neuraminidase inhibitor (LANI), CS8958, an antiviral influenza treatment, has completed enrolment for its Phase II clinical study in Japan. The Phase II trial commencement was advised in an ASX Release on 22 November 2007.

Biota Holdings Limited (ASX: BTA) and MedImmune, Inc. (Nasdaq: MEDI) announced today that they have entered into a licensing and collaboration agreement to develop and commercialise Biota's small molecule compounds designed to prevent and treat respiratory syncytial virus (RSV) infection.

Biota (ASX: BTA) reported today that the French government has announced that it intends to increase its pandemic stockpile of Relenza from 200,000 units to 9 million units over the next two years 1.